<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Research Services Division</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1EC8B4BA-7F9F-439C-87B6-339E76EBB5C4"><gtr:id>1EC8B4BA-7F9F-439C-87B6-339E76EBB5C4</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Dutka</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5E276E4B-FE32-4343-8604-D30D82621A8A"><gtr:id>5E276E4B-FE32-4343-8604-D30D82621A8A</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Finer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5FB1E0BA-FEB5-48CA-A750-72009C384555"><gtr:id>5FB1E0BA-FEB5-48CA-A750-72009C384555</gtr:id><gtr:firstName>Sadaf</gtr:firstName><gtr:surname>Farooqi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/79D70393-E85C-420E-80E1-C9A4F36E5E4D"><gtr:id>79D70393-E85C-420E-80E1-C9A4F36E5E4D</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Gribble</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/97B75EC8-E0CC-4F3B-B61D-842D1AE1C0EA"><gtr:id>97B75EC8-E0CC-4F3B-B61D-842D1AE1C0EA</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>O Sullivan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7FF3B474-C02C-4889-8C57-D0FA95DA42FD"><gtr:id>7FF3B474-C02C-4889-8C57-D0FA95DA42FD</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Schofield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8FA3036-1E74-43EA-AF45-883593A31BA6"><gtr:id>B8FA3036-1E74-43EA-AF45-883593A31BA6</gtr:id><gtr:firstName>Mark Lewis</gtr:firstName><gtr:surname>Evans</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70E289D5-CF89-4D66-A735-61746489C1EA"><gtr:id>70E289D5-CF89-4D66-A735-61746489C1EA</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>White</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701720"><gtr:id>5CCAAC92-E8CF-4B9B-955B-EEA12A719080</gtr:id><gtr:title>Investigation of the effect of GLP-1 on left ventricular function during myocardial ischaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701720</gtr:grantReference><gtr:abstractText>Cardiovascular disease is the most common cause of death in patients with diabetes mellitus, and the combination of type 2 diabetes mellitus (T2DM) and coronary artery disease is a major cause of premature cardiovascular mortality. In fact, coronary artery disease accounts for 75% of all deaths in patients with diabetes mellitus, and approximately 20% to 25% of all patients admitted to coronary care have diabetes. These patients have more severe coronary artery disease and diabetes is an important independent predictor for death, myocardial infarction or readmission with unstable angina at 1 year. Population studies support a strong, independent relationship between the concentration of glucose in the blood and subsequent long-term mortality in patients with ischemic heart disease. A heart attack is the result of prolonged interruption of blood flow to heart muscle leading to an imbalance between myocardial oxygen supply and demand. A temporary imbalance, when oxygen demand exceeds supply, is termed ischaemia and may be clinically apparent as angina. The initial response of the heart muscle to ischaemia is to increase glucose extraction in order to both support contractile function and restore intracellular metabolism. Glucagon-like peptide-1 (GLP-1) is a natural hormone released by the upper intestine in response to food ingestion that has been shown to promote glucose metabolism in the heart and the proposed studies will assess whether administration of the peptide during angina will protect the heart. The pharmacological properties of GLP-1 are attractive and this study will examine the effect of GLP-1 on cardiac performance in humans with coronary artery disease (including those with T2DM) and assess the potential of the peptide to protect the heart from damage associated with ischaemia. This is particularly important in patients with angina at rest, but also during percutaneous coronary intervention (PCI, also know as coronary angioplasty) where the coronary artery is briefly occluded during the treatment and in a significant minority of patients there is myocardial damage with release of cardiac-specific markers such as troponin into the blood. Such patients exhibit an impaired prognosis despite apparently having successful stent deployment and it is important to investigate whether infusion of GLP-1 has the potential to limit myocardial damage during PCI. If there is evidence of benefit, larger clinical trials will be required including those patients with T2DM who are at the greatest risk.</gtr:abstractText><gtr:technicalSummary>Cardiovascular disease is the most common cause of death in patients with diabetes mellitus, and the combination of type 2 diabetes mellitus (T2DM) and coronary artery disease is a major cause of premature cardiovascular mortality. In fact, coronary artery disease accounts for 75% of all deaths in patients with diabetes mellitus, and approximately 20% to 25% of all patients admitted to coronary care have diabetes. These patients have more severe coronary artery disease and diabetes is an important independent predictor for death, myocardial infarction or readmission with unstable angina at 1 year. Epidemiological analyses support a strong, independent relationship between glucose levels and long-term mortality in patients with ischemic heart disease. Myocardial infarction (MI) is the result of prolonged myocardial ischaemia, that itself follows an imbalance between myocardial oxygen supply and demand. Ischaemia exerts its adverse effects by a host of metabolic changes, starting with a breakdown of myocardial energy stores. Measures that conserve ATP during ischaemia should therefore improve LV performance and reduce the damaging consequences of acute myocardial ischaemia. The initial response of the myocardium to a lack of oxygen is an increase in glucose utilisation and provision of anaerobic energy by glycolysis. Glucose extraction by ischaemic myocardium increases as perfusion declines and insulin promotes myocardial glucose utilisation and suppresses circulating plasma free fatty acid concentration. In moderate-to-severe ischaemia, there is increased utilisation by the myocardium of glucose as a substrate for energy production although fatty acid oxidation continues to be the predominant energy substrate. In addition to the higher oxygen expenditure to generate energy than glucose metabolism, high levels of free fatty acid (FFA) catabolism during ischaemia may have detrimental effects on the myocardium and a reduction in the contractile function of myocardial segments. Cardiac efficiency is decreased because ATP is required not only to support contractile function, but increasingly to restore cellular ionic homeostasis. GLP-1 has both insulinomimetic and insulinotropic actions and the effects are dependent on the prevailing glucose concentration minimizing risks of hypoglycemia and the need for exogenous glucose administration. Thus, the pharmacological properties of GLP-1 are attractive as a means to stimulate myocardial glucose uptake during ischaemia. Therefore, the aim of this study is to examine the effect of GLP-1 on ischaemic LV dysfunction in humans with coronary artery disease and assess the potential of the peptide to limit myocardial damage during percutaneous coronary intervention (PCI).</gtr:technicalSummary><gtr:fund><gtr:end>2011-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99771</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D6EC469D-80DD-4F8E-A779-AD5ABCFA3BED</gtr:id><gtr:title>Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c04980b8e3651c653827adf3187b93ff"><gtr:id>c04980b8e3651c653827adf3187b93ff</gtr:id><gtr:otherNames>Read PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>pm_15723_23_21561896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6CE3190-F246-4968-B29F-5C5FBB5703F2</gtr:id><gtr:title>A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular interventions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c04980b8e3651c653827adf3187b93ff"><gtr:id>c04980b8e3651c653827adf3187b93ff</gtr:id><gtr:otherNames>Read PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1941-7640</gtr:issn><gtr:outcomeId>pm_15723_23_21586690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B25F1E5C-2279-42C3-83B6-818AF9DC9645</gtr:id><gtr:title>DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c04980b8e3651c653827adf3187b93ff"><gtr:id>c04980b8e3651c653827adf3187b93ff</gtr:id><gtr:otherNames>Read PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1941-9651</gtr:issn><gtr:outcomeId>KFv2eojC6SL</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701720</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>